Kornimate/medical-research-clean huggingface dataset:
the effect of pelvic floor physiotherapy on vaginal elasticity

Conditions: Stress Urinary Incontinence

Summary: women suffering from stress urinary incontinence are offered pelvic floor physiotherapy as an optional treatment. strengthening of the pelvic floor is measured to date by manual examination and lacks precise evaluation. the vaginal tactile imager assists in evaluation of the changes in the pelvic floor after physiotherapy.

women with stress urinary incontinence will undergo 6-10 pelvic floor strengthening physiotherapy sessions. the participants will undergo a short examination of vaginal elasticity using a vaginal tactile imager prior to beginning physiotherapy and additional examinations after 6 treatments, 10 treatments and 3 and 6 months post-treatment cessation.

Eligibility criteria:
inclusion criteria: * women suffering from stress urinary incontinence. exclusion criteria: * women suffering from urge urinary incontinence. * women suffering of mixed urinary incontinence.
paralysis of the orbicularis muscle of the eye in the treatment for dry eye

Conditions: Dry Eye Syndromes

Summary: this is a prospective, comparative, contralateral eye study. patients older than 18 years who have had treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein were included. patients with dry eye attributable to abnormalities of the eyelids, nasolacrimal obstruction and active corneal infection, as well as patients with severe dry eye were excluded from the study. one eye randomly received a subcutaneous injection of botulinum toxin in the medial part of the lower eyelid, and the other eye received a similar procedure with placebo. the subjective evaluation was achieved with a questionnaire assessing symptoms of dry eye and conjunctivitis, quality of vision and ocular comfort level each eye separately. the objective evaluation included the measurement of the tear film break up time, schirmer's test and with a modification of the oxford grading scheme for corneal and conjunctival staining.


Eligibility criteria:
inclusion criteria: * treatment with topical lubricants for at least 1 month and persist with symptoms of dry eye and corneal staining with fluorescein. exclusion criteria: * dry eye patients attributable to abnormalities of the eyelids (problems with the mechanism of blinking, poor eyelid position, changes in position or structure of the eyelashes, high surface lesions, etc.) * nasolacrimal obstruction. * active corneal infection. * patients with severe grade 4 dry eye.

Keywords: dry eye botulinum toxin a orbicularis muscle of the eye
validation of electrical cardiometry versus fick method in cardiac output measurement

Conditions: Heart Failure

Summary: the investigators would like to find out if aesculon®, a new device that non-invasively and continuously measures cardiac output using electrical cardiometry, works as well as one existing method--fick method in patients undergoing cardiopulmonary exercise testing.


Eligibility criteria:
inclusion criteria: * age \>= 18 yd; * level 3 cardiopulmonary exercise testing. exclusion criteria: * proven or suspected disease involving severe aortic regurgitation; * implanted with a rate-responsive cardiac pacemaker; * pneumothorax or pleural effusion; * skin lesion(s) at the place where the electrode is supposed to be applied; * allergic to adhesive of ecg electrodes.

Keywords: cardiopulmonary exercise test cardiac output
effect of oxiris® membrane on microcirculation following cardiac surgery under cardiopulmonary bypass: a pilot prospective monocentric study (oxicard study).

Conditions: Surgery; Cardiac Event

Summary: oxiris membrane is an efficient tool for inflammatory cytokines adsorption. cardiac surgery is followed by an inflammatory state mimicking sepsis. the investigators hypothesized that cytokine adsorption by oxiris® membrane can attenuate the inflammatory response and thus decrease the microcirculation impairment that followed cardiac surgery.

oxiris membrane is an efficient tool for inflammatory cytokines adsorption. cardiac surgery is followed by an inflammatory state mimicking sepsis. the investigators hypothesized that cytokine adsorption by oxiris® membrane can attenuate the inflammatory response and thus decrease the microcirculation impairment that followed cardiac surgery.

Eligibility criteria:
inclusion criteria: * patients with more than 18 years old * elective cardiac surgery under cpb with an expected cpb time \> 90 minutes (double valve replacement or valve replacement plus coronary arterial bypass graft (cabg)) * written informed consent from patient or legal surrogates exclusion criteria: * missing informed consent. * planned cpb hypothermia \<32ºc * emergency surgery. * acute infective endocarditis. * immunosuppressive treatment or steroids (prednisone \> 0.5 mg/kg/day or equivalent). * aids with a cd4 count of \< 200/ μl * autoimmune disorder. * transplant receptor. * advanced chronic kidney disease (ckd 4 or 5). * renal replacement therapy (rrt) in the last 90 days. * documented intolerance to study device. * inclusion in other ongoing study within the last 30 days. * pregnancy. * coexisting illness with a high probability of death (inferior to 6 months).
safety and tolerability study of abt-089 in children with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention-Deficit/Hyperactivity Disorder

Summary: the purpose of this study is to test if the investigational medication abt-089 is a safe and effective treatment for children with attention deficit hyperactivity disorder (adhd).


Eligibility criteria:
inclusion criteria: * have voluntarily signed an informed consent form. * meet diagnostic criteria for attention-deficit/hyperactivity disorder (adhd) based on detailed evaluation and interview with parent(s). * subject is generally in good health based on medical history, physical examination, clinical lab tests and ecg. * subject weights at least 37 pounds (17 kg) * female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. * subject can swallow pills and subjects and parents are able to keep required appointments for clinic visits and all tests, including blood draws and examinations. exclusion criteria: * subject has a current or past diagnosis of bipolar disorder, psychosis, autism, asperger syndrome, pervasive developmental disorder, tics, tourette syndrome, mental retardation, seizure disorder or traumatic brain injury. * current diagnosis of obsessive-compulsive disorder, eating disorder, anxiety disorder or depressive disorder requiring treatment of any kind. * subject has a history of, or ongoing, serious medical problem. * subject has a history of significant allergic reaction to any drug. * subject is planning to begin any type of behavioral or psychotherapy for treatment of adhd. * subject requires ongoing treatment with any psychiatric medication.
chronic migraines and neurofdeeback mindfulness

Conditions: Chronic Migraine, Headache

Summary: as the second phase of our study on migraine headaches and neurofeedback mindfulness, we will explore how chronic migraineurs will benefit from a long term practice (8 weeks) of neurofeedback mindfulness compared to a similar attention group and a waitlisted group. this randomized controlled trial will also explore if migrianuers could decrease their dependence on medicine intake after completion of the study.


Eligibility criteria:
inclusion criteria: * have a diagnosis of chronic migraine from a clinician or have met the criteria for a chronic migraine diagnosis based on ichd-3 * reside in saskatoon area * have a smartphone and internet connection for accessing the muse app * have no frequent background experience of meditation exclusion criteria: * comorbidity of raynaud's syndrome or diabetes * current use of a preventative migraine treatment over 6 months

Keywords: neurofeedback mindfulness headache management self-efficacy chronic migraines dependence behaviours migraine severity
study to evaluate the benefits for the patient associated with the treatment of plaque psoriasis with apremilast after other systemic treatment in conditions of clinical practice in spain

Conditions: Psoriasis

Summary: observational, prospective and multicenter study in approximately 30 sites nationwide. the investigators participating in this study will be dermatologists specializing in this pathology. the present study will include adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice. recruitment will be consecutive and the reason for not including a potential candidate patient will be registered. the decision to prescribe apremilast treatment should be clearly dissociated from the inclusion of the patient in the study. therefore, the choice of the therapeutic strategy will be made independently by the physician.


Eligibility criteria:
inclusion criteria: * adult male and female (≥ 18 years). * patients diagnosed with moderate to severe plaque psoriasis and for which treatment with apremilast is indicated according to the doctor's criteria (established before the patient enters the study) and according to the specifications of the medication's data sheet * patients with available data regarding the pasi and dlqi assessments at the moment of initiating treatment with apremilast. * patients for whom, according to the physician's criteria (established prior to patient's entry into the study) and according to the specifications of the drug's prescribing information, apremilast treatment is indicated. * all patients who, according to the routine clinical practice, initiated apremilast treatment for the first time 3 months (+/- 4 weeks) before their inclusion in the study (patients may or may not have completed 3 months of apremilast treatment). * patients who have previously received at least one systemic treatment for moderate to severe plaque psoriasis. * patients who have not previously been treated with a biological agent for moderate to severe plaque psoriasis. * patients who agree to participate in the study by signing the informed consent. * patients who are able to understand and complete the questionnaires specified in the study protocol. exclusion criteria: • patients participating in another study at the time of entering the study.

Keywords: psoriasis plaque psoriasis apremilast cc-10004
treatment of acute pharyngo-tonsillitis with essential oils of aromatic plants

Conditions: Viral Pharyngitis; Viral Tonsillitis

Summary: this randomized, double blind, parallel group study, compared the efficacy of spray containing aromatic essential oils of some herbal plants, against placebo in the treatment of patients with acute viral pharyngo-tonsillitis. study objectives: primary to demonstrate a throat pain relief within 20 minutes after first administration of treatment with the spray. secondary to demonstrate a reduction of a defined symptoms sum score based on symptoms and signs comparing baseline therapy from the beginning to the end of 3 days treatment

this study compared the efficacy of spray containing aromatic essential oils of eucalyptus citriodora, eucalyptus globulus, mentha piperita, origanum syriacum, and rosmarinus officinalis, against placebo in the treatment of patients with acute viral pharyngo-tonsillitis. in- vitro and clinical studies suggest therapeutic potential of aromatic herbs and trees oils in the treatment of pharyngo-tonsillitis. the pharmacological and clinical activity of eucalyptus citriodora, eucalyptus globulus, mentha piperita, origanum syriacum, and rosmarinus officinalis, include anti-inflammatory, anti-bacterial and anti-viral activities. some of these herbs and trees oils have direct activity on the respiratory tract, the coughing reflex and the airflow in the nasal tract.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute viral pharyngo-tonsillitis. * active disease less than 48 hours * patients agree to sign informed consent according to gcp and israel national regulations. exclusion criteria: * acute follicular tonsillitis. * peritonsillar abscess. * under any antibiotically treatment. * asthma disease. * under coumadine therapy. * hyper sensitivity to aromatic essential oils. * any immuno-suppressive disease

Keywords: viral pharyngo-tonsillitis; herbal medicine; traditional medicine; aromatic essential oils;
efficacy and safety study of lumiracoxib in patients with primary hip osteoarthritis

Conditions: Osteoarthritis, Hip

Summary: the purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. both lumiracoxib and celecoxib belong to the same class of drug (cox-2 selective nonsteroidal anti-inflammatory drugs \[nsaids\]).


Eligibility criteria:
inclusion criteria: * diagnosis of primary hip osteoarthritis * qualifying pain intensity in the hip joint * requiring nsaid therapy exclusion criteria: * rheumatoid arthritis or other inflammatory joint disease * disease or disorder that may interfere with pain assessment of the hip * open knee/hip surgery within the last year * past history of heart attack, stroke or angina (chest pain) * liver disorder * history of severe adverse reactions of any kind under lumiracoxib or celecoxib treatment other protocol-defined exclusion criteria may apply.

Keywords: osteoarthritis, hip, lumiracoxib, efficacy, safety
orange almond potato cookies supplementation

Conditions: Nutritional Stunting

Summary: the goal of this clinical trial is to assess the effect of potato almond orange cookie supplementation on the nutritional status of stunted under-five children. the main questions aimed to answer are: * can cookie supplementation improve the weight of stunted under-five children? * can cookie supplementation improve the weight for age z score of stunted under-five children? participants divided in the two groups i.e.: * treatment group received 50 g potato almond orange cookie each day during 4 weeks. * control group received 50 g potato orange cookie each day during 4 weeks. * mothers of both groups given balanced nutrition education for stunted under-five children twice at the second and third week of study.

treatment group received 50 g potato almond orange cookie each day during 4 weeks. control group received 50 g potato orange cookie each day during 4 weeks.

Eligibility criteria:
inclusion criteria: * age in the range of 12-59 months * male and female * lived in sawangan lama, depok, and depok jaya neighborhoods of depok city (three urban villages with a large stunting prevalence) * had a height-for-age z-score (haz) index of \< -2 sd * were not suffering from chronic or infectious diseases. exclusion criteria: * suffered from chronic or infectious diseases

Keywords: covid19 stunted under-five children weight haz score orange almond potato cookies
alcohol and cigarette craving during oxytocin treatment

Conditions: Alcohol Use Disorder; Smoking

Summary: this proposed research seeks to examine the behavioral and neural substrates of intranasal oxytocin compared to placebo on alcohol cue-induced alcohol and cigarette craving smokers with an alcohol use disorder (aud). non treatment-seeking smokers with an aud will be recruited to participate in a between-subjects, placebo-controlled, randomized pilot functional magnetic resonance imaging (fmri) study. participants will undergo an fmri scan in conjunction with an alcohol-olfactory cue-reactivity task. secondary assessments will include alcohol and cigarette craving, alcohol and cigarette consumption, physiological measures (heart rate and blood pressure) and mood measures.


Eligibility criteria:
inclusion criteria: 1. male or female 2. 18 to 55 years of age 3. meet criteria for alcohol use disorder dsm-5 diagnosis 4. meet the national institute on alcohol abuse and alcoholism criteria for heavy-drinking 5. smoke at least ≥5 cigarettes/day for at least a year, verified with breath carbon monoxide level \> 5 ppm 6. in good health as confirmed by medical history, physical examination and lab tests 7. willing to take the medication and adhere to the study procedures 8. breath alcohol concentration (brac) = 0.00 at each visit 9. understand informed consent and questionnaires written in english at an 8th grade level 10. right-handedness 11. normal to normal-corrected vision exclusion criteria: 1. positive urine test for pregnancy 2. women who are breast-feeding 3. body mass index \> 40 4. current or prior history of any clinically significant disease, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or reproductive disorders, positive hepatitis or hiv test that could affect study participation, as determined by the study physician 5. history of suicide attempts 6. current diagnosis of substance dependence other than alcohol, nicotine or cannabis as assessed by self-report and urine toxicology screen at baseline 7. current use of psychoactive medications or any medication that may interact with oxytocin 8. history of hypersensitivity to oxytocin 9. chronic rhinitis or sinusitis 10. clinically significant electrolyte abnormalities 11. vasoconstricting medications or prostaglandins 12. clinically significant medical abnormalities: unstable hypertension, bilirubin \>150% of the upper normal limit (unl), alt/ast \>500% the unl, creatinine clearance ≤60 dl/min) 13. significant alcohol withdrawal symptoms, defined as a ciwa-ar \> 8 14. positive urine drug screen at baseline for any excluded substances 15. individuals seeking treatment 16. meets dsm-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses 17. claustrophobia 18. any contraindications with the mri machine

Keywords: oxytocin craving alcohol use disorder smoking cigarettes drinking functional magnetic resonance imaging cue-reactivity
qor-9 as predictor of postoperative complications

Conditions: Postoperative Complications

Summary: aim of the study is to evaluate, whether the self administered quality of recovery (qor-9) questionnaire can predict postoperative complications after non-cardiac surgery and whether preoperative risk estimates can be improved by implementation of the qor-9 as postoperative screening tool.

the qor-9 as established patient-centred outcome measure, which is validated in german language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. we showed in a pilot study that this score reveals a high sensitivity to detect patients with a disturbed health status through a detailed and time-consuming physical examination.we want to evaluate if short screening tools can be used to categorize patients with increased risk for developing postoperative complicationstherefore, patients undergoing non-cardiac surgery are informed preoperatively about the study and written informed consent is obtained. afterwards, the qor-9, as well as validated preoperative risk scores are obtained. relevant intra- and immediate postoperative factors are recorded. on postoperative day 1 and 3 patients perform the qor-9. postoperative complications during hospital stay are determined using the clavien dindo score by searching the patients 'record. after 6 months the patients are contacted via telephone and the qor-9 is obtained. 6-months mortality is determined.

Eligibility criteria:
inclusion criteria: * written informed consent * undergoing non-cardiac surgery * good knowledge of german language exclusion criteria: * blind * out-patient * pregnant * psychiatric disturbance that preclude cooperation * decline to participate

Keywords: outcome postoperative complications failure to rescue qor-9 patient-centred questionnaire
the effects of the electro, heat and cold -therapy during physiotherapy treatment in osteoarthritis(oa) of knee

Conditions: Knee Pain; Osteoarthritis

Summary: the objective of this clinical trial is to evaluate the pain relief and daily functioning improve, in patients suffering of osteoarthritis of knee, with hot/cold/ electro therapy during physiotherapy treatment

prospective randomize trial. the patients with knee pain and osteoarthritis, that were referred to the physiotherapy treatment. each patient will be checked twice by the physiotherapy team, in the first and in the last physiotherapy treatment. test muscle strength of quadriceps, gluteous medius and hamstring will be measured by dynamometer (the dynamometer expressed in a quantitative way the muscle force) the population will randomized separated in trail and control group. the control group will receive before physiotherapy cold hot or electrotherapy treatment depends on the patient and physiotherapy prefer. the trial group will receive with elf_care unit (hot-cold \& electrotherapy) during physiotherapy treatment ( 28 minutes twice a week) the protocol treatment includes 28 minutes of cycling cold/hot/cold/hot treatment (2\*7 min cold: 10...15 degrees; 2\*7 min hot: 39..42 degrees,). during this 28 minutes the patient also receive tolerable intensity premodulated interferential current with sweep beat frequency (3hz...200hz), carrier frequency 5khz ; electrodes setup: thermo electrode and 2 regular electrodes after the treatment the control and trail group will evaluate with 0-10 visual analogue scale vas, oxford knee score and womac the population will receive treatment twice a week for one month.

Eligibility criteria:
inclusion criteria: * male or female patients more than 60 years old * patients suffering from knee pain due to osteoarthritic changes in radiographic plains. * patients in medical condition to receive physiotherapy treatment * patients who are willing to participate in the trial, to come to all scheduled visits and to sign the informed consent forms. exclusion criteria: * patients receiving other methods of treatment to this area, * patients with concomitant other injury of the knee. * dermatological affection with contraindication use of hot, cold and/or electrical stimulation * non cooperative patient with the basic rehab program.

Keywords: cold hot or electrotherapy treatment
neulasta in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the primary purpose of this study is to find out if giving a 12 week course of neulasta (pegylated granulocyte colony stimulating factor (gcsf)) to people with type 1 diabetes (t1d) is safe. the secondary purpose of this research study is to determin if giving gcsf to patients with t1d changes the immune system or preserves insulin production.

as a participant in this study the following will happen: blood test, mixed meal tolerance test (mmt) to find out how much c-peptide is being produced, human leukocyte antigen (hla) test, hemoglobin a1c (hba1c) test for overall blood sugar control, and randomized to either receive the 12 week course of neulasta (pegylated granulocyte colony stimulating factor (gcsf)) or a placebo (no medication).

Eligibility criteria:
inclusion criteria: * must be \> 12 years old and have a confirmed diagnosis of "recent onset t1d" as defined by: * t1d for \< 6 months, * stimulated c-peptide ≥ 0.2 pmol/ml * presence of at least one diabetes-related autoantibody (e.g., gad, ia-2, iaa, ica) * normal screening values for cbc * willing to comply with intensive diabetes management * no history of allergy to gcsf * females having reproductive potential must be willing to avoid pregnancy and have a negative pregnancy test exclusion criteria: * known hypersensitivity to e.coli-derived proteins, pegfilgrastim, filgrastim, or any other component of the product * chronic use of steroids or other immunosuppressive agents * active infection * inability to maintain intensive diabetes management * pregnancy * history of malignancy * currently participating in another type 1 diabetes treatment study. * use of non-insulin pharmaceuticals that affect glycemic control